

## Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting

**GOTHENBURG, SWEDEN - As announced in a press release on 22 April 2025, the Board of Directors of LIDDS AB (publ) ("Lidds" or the "Company") found reason to believe that the equity was less than half of the registered share capital and therefore decided to prepare a balance sheet for liquidation purposes. The Board of Directors of Lidds has prepared the balance sheet for liquidation purposes, and it has been reviewed by the Company's auditor. The balance sheet for liquidation purposes shows that the Company's equity is less than half of the registered share capital of SEK 7,232,556.**

Lidds and the Board of Directors have worked intensively during the spring to try to generate equity for the Company but have not yet found a solution for its strained financial situation in the short and medium term. The Board of Directors will therefore convene a general meeting (the so-called first control meeting according to the Swedish Companies Act). The notice of the Annual General Meeting, which will also serve as the First Control Meeting, will be published through a separate press release shortly.

**For additional information, please contact**

---

Mats Wiking, CEO and CFO  
Phone: +46 (0)70 620 04 00  
E-mail: [mats.wiking@liddspharma.com](mailto:mats.wiking@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

### **LIDDS in brief:**

---

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

*This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 22:45 CEST.*

## **Attachments**

---

**Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting**